Italian biotechnology firm Newron Pharmaceuticals will receive €1,833,160 ($2,465,462) from the European Commission to develop an “innovative integrated system for efficient high-throughput screening of molecules for ion channel targets,” the company said last week.

Newron, which focuses primarily on CNS-related drug discovery, will use the funding to manage a consortium of “small-to-medium enterprises” and universities from five European countries — Italy, Germany, Romania, Hungary, and Poland — as part of a research initiative dubbed the ION project.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.